Albumin therapy for sepsis-related lung injury on a ventilator
Part of Blood & lymphatic, Infections, Lungs & breathing clinical trials.
This trial tests whether giving albumin, a protein in the blood that helps keep fluid in the vessels, can improve outcomes for people with sepsis-related lung injury (ARDS) who are on a breathing machine. If you have low albumin levels, this therapy might help your lungs recover.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have sepsis (a severe infection affecting your whole body) and a lung injury called ARDS (acute respiratory distress syndrome), which makes it hard to breathe.
- You are on a breathing machine (ventilator) and have been for 48 hours or less.
- You have been in the intensive care unit (ICU) for 24 hours or less.
- Your albumin level (a protein in your blood) is 30 g/L or lower.
- You are expected to need ICU care for more than 48 hours.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment to protect and repair the layer of cells lining your blood vessels (glycocalyx) during sepsis. It aims to improve recovery from severe infections.
This study looks at the early changes in the lungs of people with sepsis who develop a severe breathing problem called ARDS. Researchers will collect small samples of lung fluid to better understand the condition and potentially improve future treatments.
This trial tests a new medicine called YD0743 for people who have both sepsis (a serious infection) and ARDS (a severe lung injury from the infection). The goal is to see if the medicine helps improve breathing and survival.
This trial tests if adding stem cells or their growth liquid to standard sepsis treatment helps adults with severe breathing problems. It may improve recovery for those whose family agrees to the study.
This trial tests whether giving albumin (a protein in the blood) along with standard fluids helps patients with septic shock after a surgical infection. The goal is to see if it improves recovery and survival compared to fluids alone.
This trial studies two ways of giving albumin (a protein given through an IV) to people with cirrhosis who also have a sudden kidney injury from sepsis. The goal is to see which method—tailored to each patient or a fixed dose—is safer and works better for kidney recovery.
Hear when a new Acute Respiratory Distress Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.